In light of clinical research showing MDMA-assisted therapy as a potential treatment for PTSD, at PSYCH Symposium in the British Museum on 6 July a conversation...
PSYCH Symposium returned at the British Museum on 6 July to explore how psychedelic medicines can innovate healthcare – from mental health to eating disorders and...
Timmy Davis of the Conservative Drug Policy Reform Group (CDPRG) tells Psychedelic Health about the organisation’s campaign to reschedule psilocybin in a bid to increase psychedelic...
In a groundbreaking milestone for psychedelics in Europe, a cross-party MEP Action Group for the Medical Use of Psychedelics was launched at an expert roundtable on...
MP Crispin Blunt raised a point of order in the House of Commons after the UK’s Drugs Minister failed to show up for a debate on...
A UK Parliamentary debate on 18 May saw crossparty calls to conduct an urgent review of the evidence for psilocybin’s current status as a Schedule 1...
The Royal College of Psychiatrists, Heroic Hearts and other leading mental health charities have written letters to the Veterans Minister and the Minister of State for...
The use of psychedelics in research has a long and storied history, dating back to the mid-20th century.
An increasing amount of research is showing psychedelics as promising treatments for a variety of mental health conditions, however, a group of experts have emphasised the...
Regulatory approvals for psychedelic medicines are becoming a reality, and the focus in policy and advocacy work is shifting from “if” to “when” and – most...